Cargando…
Neuroprotective Efficacy of a Nanomicellar Complex of Carnosine and Lipoic Acid in a Rat Model of Rotenone-Induced Parkinson’s Disease
Oxidative stress, accompanied by mitochondrial dysfunction, is a key mechanism involved in the pathogenesis of Parkinson’s disease (PD). Both carnosine and lipoic acid are potent antioxidants, the applicability of which in therapy is hindered by their limited bioavailability. This study aimed to eva...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294933/ https://www.ncbi.nlm.nih.gov/pubmed/37371945 http://dx.doi.org/10.3390/antiox12061215 |
_version_ | 1785063300638179328 |
---|---|
author | Kulikova, Olga Troshev, Dmitry Berezhnoy, Daniil Stvolinsky, Sergey Timoshina, Yulia Abaimov, Denis Muzychuk, Olga Latanov, Alexander Fedorova, Tatiana |
author_facet | Kulikova, Olga Troshev, Dmitry Berezhnoy, Daniil Stvolinsky, Sergey Timoshina, Yulia Abaimov, Denis Muzychuk, Olga Latanov, Alexander Fedorova, Tatiana |
author_sort | Kulikova, Olga |
collection | PubMed |
description | Oxidative stress, accompanied by mitochondrial dysfunction, is a key mechanism involved in the pathogenesis of Parkinson’s disease (PD). Both carnosine and lipoic acid are potent antioxidants, the applicability of which in therapy is hindered by their limited bioavailability. This study aimed to evaluate the neuroprotective properties of a nanomicellar complex of carnosine and lipoic acid (CLA) in a rotenone-induced rat model of PD. Parkinsonism was induced via the administration of 2 mg/kg rotenone over the course of 18 days. Two doses of intraperitoneal CLA (25 mg/kg and 50 mg/kg) were administered alongside rotenone to assess its neuroprotective effect. At 25 mg/kg CLA decreased muscle rigidity and partially restored locomotor activity in animals that received rotenone. Furthermore, it caused an overall increase in brain tissue antioxidant activity, accompanied by a 19% increase in neuron density in the substantia nigra and increased dopamine levels in the striatum relative to animals that only received rotenone. Based on the acquired results, it may be concluded that CLA have neuroprotective properties and could potentially be beneficial in PD treatment when used in conjunction with the base therapy. |
format | Online Article Text |
id | pubmed-10294933 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102949332023-06-28 Neuroprotective Efficacy of a Nanomicellar Complex of Carnosine and Lipoic Acid in a Rat Model of Rotenone-Induced Parkinson’s Disease Kulikova, Olga Troshev, Dmitry Berezhnoy, Daniil Stvolinsky, Sergey Timoshina, Yulia Abaimov, Denis Muzychuk, Olga Latanov, Alexander Fedorova, Tatiana Antioxidants (Basel) Article Oxidative stress, accompanied by mitochondrial dysfunction, is a key mechanism involved in the pathogenesis of Parkinson’s disease (PD). Both carnosine and lipoic acid are potent antioxidants, the applicability of which in therapy is hindered by their limited bioavailability. This study aimed to evaluate the neuroprotective properties of a nanomicellar complex of carnosine and lipoic acid (CLA) in a rotenone-induced rat model of PD. Parkinsonism was induced via the administration of 2 mg/kg rotenone over the course of 18 days. Two doses of intraperitoneal CLA (25 mg/kg and 50 mg/kg) were administered alongside rotenone to assess its neuroprotective effect. At 25 mg/kg CLA decreased muscle rigidity and partially restored locomotor activity in animals that received rotenone. Furthermore, it caused an overall increase in brain tissue antioxidant activity, accompanied by a 19% increase in neuron density in the substantia nigra and increased dopamine levels in the striatum relative to animals that only received rotenone. Based on the acquired results, it may be concluded that CLA have neuroprotective properties and could potentially be beneficial in PD treatment when used in conjunction with the base therapy. MDPI 2023-06-04 /pmc/articles/PMC10294933/ /pubmed/37371945 http://dx.doi.org/10.3390/antiox12061215 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kulikova, Olga Troshev, Dmitry Berezhnoy, Daniil Stvolinsky, Sergey Timoshina, Yulia Abaimov, Denis Muzychuk, Olga Latanov, Alexander Fedorova, Tatiana Neuroprotective Efficacy of a Nanomicellar Complex of Carnosine and Lipoic Acid in a Rat Model of Rotenone-Induced Parkinson’s Disease |
title | Neuroprotective Efficacy of a Nanomicellar Complex of Carnosine and Lipoic Acid in a Rat Model of Rotenone-Induced Parkinson’s Disease |
title_full | Neuroprotective Efficacy of a Nanomicellar Complex of Carnosine and Lipoic Acid in a Rat Model of Rotenone-Induced Parkinson’s Disease |
title_fullStr | Neuroprotective Efficacy of a Nanomicellar Complex of Carnosine and Lipoic Acid in a Rat Model of Rotenone-Induced Parkinson’s Disease |
title_full_unstemmed | Neuroprotective Efficacy of a Nanomicellar Complex of Carnosine and Lipoic Acid in a Rat Model of Rotenone-Induced Parkinson’s Disease |
title_short | Neuroprotective Efficacy of a Nanomicellar Complex of Carnosine and Lipoic Acid in a Rat Model of Rotenone-Induced Parkinson’s Disease |
title_sort | neuroprotective efficacy of a nanomicellar complex of carnosine and lipoic acid in a rat model of rotenone-induced parkinson’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294933/ https://www.ncbi.nlm.nih.gov/pubmed/37371945 http://dx.doi.org/10.3390/antiox12061215 |
work_keys_str_mv | AT kulikovaolga neuroprotectiveefficacyofananomicellarcomplexofcarnosineandlipoicacidinaratmodelofrotenoneinducedparkinsonsdisease AT troshevdmitry neuroprotectiveefficacyofananomicellarcomplexofcarnosineandlipoicacidinaratmodelofrotenoneinducedparkinsonsdisease AT berezhnoydaniil neuroprotectiveefficacyofananomicellarcomplexofcarnosineandlipoicacidinaratmodelofrotenoneinducedparkinsonsdisease AT stvolinskysergey neuroprotectiveefficacyofananomicellarcomplexofcarnosineandlipoicacidinaratmodelofrotenoneinducedparkinsonsdisease AT timoshinayulia neuroprotectiveefficacyofananomicellarcomplexofcarnosineandlipoicacidinaratmodelofrotenoneinducedparkinsonsdisease AT abaimovdenis neuroprotectiveefficacyofananomicellarcomplexofcarnosineandlipoicacidinaratmodelofrotenoneinducedparkinsonsdisease AT muzychukolga neuroprotectiveefficacyofananomicellarcomplexofcarnosineandlipoicacidinaratmodelofrotenoneinducedparkinsonsdisease AT latanovalexander neuroprotectiveefficacyofananomicellarcomplexofcarnosineandlipoicacidinaratmodelofrotenoneinducedparkinsonsdisease AT fedorovatatiana neuroprotectiveefficacyofananomicellarcomplexofcarnosineandlipoicacidinaratmodelofrotenoneinducedparkinsonsdisease |